Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Common Equity (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Common Equity for 13 consecutive years, with -$6.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 15.74% to -$6.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.6 million, a 15.74% decrease, with the full-year FY2025 number at -$6.3 million, down 20.39% from a year prior.
  • Common Equity was -$6.6 million for Q4 2025 at Regen BioPharma, down from -$6.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $5.0 in Q1 2021 to a low of -$76.7 million in Q1 2022.
  • A 5-year average of -$10.0 million and a median of -$5.7 million in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 100.0% in 2021, then tumbled 1534988700.0% in 2022.
  • Regen BioPharma's Common Equity stood at -$9.8 million in 2021, then soared by 49.93% to -$4.9 million in 2022, then fell by 7.3% to -$5.2 million in 2023, then dropped by 8.35% to -$5.7 million in 2024, then fell by 15.74% to -$6.6 million in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Common Equity are -$6.6 million (Q4 2025), -$6.3 million (Q3 2025), and -$5.8 million (Q2 2025).